肥大细胞在肠易激综合征中的作用研究进展

被引：17

作者：

张小雨

高源

齐云

机构：

[1] 中国医学科学院北京协和医学院药用植物研究所

来源：

中国药理学通报 | 2020年 / 36卷 / 02期

关键词：

肠易激综合征; 肥大细胞; 发病机制; 治疗; 胰蛋白酶; 组胺;

D O I：

暂无

中图分类号：

R574.4 [肠道功能紊乱];

学科分类号：

100201 [内科学];

摘要：

肠易激综合征(irritable bowel syndrome,IBS)是一种多因素相互作用的胃肠道功能紊乱性疾病,全球范围内发病率较高。其发病机制复杂,如内脏高敏感、胃肠道动力异常、肠道屏障损坏、肠道免疫紊乱、神经免疫失调等。研究表明,肥大细胞(mast cells,MCs)在IBS的发生与发展中起到重要作用,在IBS治疗中也有初步尝试。该文就MCs在IBS发病机制中的作用及针对MCs的IBS治疗方案进行综述。

引用

页码：149 / 153

页数：5

共 10 条

[1]

神经肽Y和5-羟色胺在腹泻型肠易激综合征模型大鼠中表达的研究 [J].

唐洪梅 ;

房财富 ;

廖小红 ;

李得堂 ;

姚楠 ;

何嘉仑 .

中国药理学通报, 2012, 28 (07) :916-920

[2]

Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study [J].

Lobo, Beatriz ;

Ramos, Laura ;

Martinez, Cristina ;

Guilarte, Mar ;

Gonzalez-Castro, Ana M. ;

Alonso-Cotoner, Carmen ;

Pigrau, Marc ;

de Torres, Ines ;

Rodino-Janeiro, Bruno K. ;

Salvo-Romero, Eloisa ;

Fortea, Marina ;

Pardo-Camacho, Cristina ;

Guagnozzi, Danila ;

Azpiroz, Fernando ;

Santos, Javier ;

Vicario, Maria .

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2017, 5 (06) :887-897

[3]

Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators [J].

Martin-Vinas, Juan J. ;

Quigley, Eamonn M. M. .

JOURNAL OF DIGESTIVE DISEASES, 2016, 17 (09) :572-581

[4]

Extra-intestinal symptoms in patients with irritable bowel syndrome: related to high total IgE levels and atopic sensitization? [J].

Vara, Ellen Johanne ;

Valeur, Jorgen ;

Hausken, Trygve ;

Lied, Gulen Arslan .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (08) :908-913

[5]

Histamine Receptor H1–Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.[J].Mira M. Wouters;Dafne Balemans;Sander Van Wanrooy;James Dooley;Vincent Cibert-Goton;Yeranddy A. Alpizar;Eduardo E. Valdez-Morales;Yasmin Nasser;Paul P. Van Veldhoven;Winde Vanbrabant;Schalk Van der Merwe;Raf Mols;Bart Ghesquière;Carla Cirillo;Inge Kortekaas;Peter Carmeliet;Willy E. Peetermans;Séverine Vermeire;Paul Rutgeerts;Patrick Augustijns;Peter

[6]

Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome [J].

Nee, Judy ;

Zakari, Mohammed ;

Lembo, Anthony J. .

EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (18) :2781-2792

[7]

Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers' diarrhoea [J].

Schwille-Kiuntke, J. ;

Mazurak, N. ;

Enck, P. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (11) :1029-1037

[8]

520 Efficacy of Ibodutant; a Selective Antagonist of Neurokinin 2 Receptors; in Irritable Bowel Syndrome With Diarrhoea (IBS-D): The Results of a Double-Blind; Randomised; Placebo-Controlled; Parallel-Group Phase II Study (the IRIS-2).[J].Jan F. Tack;Yavor S. Dochev;Anna Bochenek;Ivan Atanasov;Marek Horynski;Pernille Lundqvist;Kai Schumacher;Isabella Otranto;Angela Capriati;Carlo Alberto Maggi.Gastroenterology.2013, 5S1

[9]

901 Effect of the H1-Receptor Antagonist Ebastin on Visceral Perception and Clinical Symptoms in IBS.[J].Sander van Wanrooij;Mira M. Wouters;Lukas Van Oudenhove;Severine Vermeire;Paul J. Rutgeerts;Guy E. Boeckxstaens.Gastroenterology.2013, 5S1

[10]

Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome [J].

Tayama, J. ;

Sagami, Y. ;

Shimada, Y. ;

Hongo, M. ;

Fukudo, S. .

NEUROGASTROENTEROLOGY AND MOTILITY, 2007, 19 (06) :471-483

← 1 →